M & A

Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.

Only days after its initial announcement, Hypera Pharma has refused EMS’ proposed merger on grounds of undervaluation and different strategic priorities.

In the wake of its recent acquisition of dermatology assets from Canute Pharma, UK-based Aspire Pharma is looking to new frontiers of expansion in Europe and beyond. Chief executive Richard Condon talks to Generics Bulletin about the next steps on the niche generics and value added medicines firm’s journey.

Three $1bn+ alliances were penned in September.

Kenvue may have to start sharing time with Bausch + Lomb in investors’ discussions about the outlook for success at US consumer health firms separated from former parent firms as they and their competitors begin reporting the results for their latest quarters.

Bodybuilding.com reintroduces itself as ‘BBCOM’ with new plans; Flashlight Capital bids to buy Korea tobacco giant’s ginseng business; Hello Cake acquires Trigg Laboratories to be vertically integrated; Actylis expands into supplements, OTCs with Pharm-Rx; Helaina adds $45M funding, launches ingredient sales; ophthalmic drug firm Scope adds Eyevitamins supplements; 5 Star Nutrition’s franchising to expand.

An interactive look at medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

Zentiva has launched a bid to take control of German “single pill company” Apontis Pharma, with a €10-per-share offer that values the enterprise at €85m. If successful, Zentiva plans to establish the firm as a standalone branded division.

This week, J&J announced that it was buying heart failure device firm V-Wave; Procept got the FDA’s OK on a clinical trial of its Aquablation treatment for prostate cancer; and CMS began to consider Medicare reimbursement of Abbott’s TriClip tricuspid repair device.

The biopharma industry posted 22 mergers and acquisitions during the third quarter, according to Evaluate, for a total of $8.2bn. Those tallies marked a second consecutive quarter of decline.